Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BISC-1
- Development stage
- Preclinical
- Lead developer
- Allegro
01
Overview
BISC-1 is an investigational Advanced Therapy Medicinal Product (ATMP) currently in the early research and development (Concept/R&D) phase, developed by Allegro. While the specific molecular target and primary indication have not been publicly disclosed, the candidate is part of a pipeline focused on high-unmet needs in rheumatology, orthopedics, musculoskeletal diseases, and neurosciences. As an ATMP, BISC-1 likely utilizes gene therapy, somatic-cell therapy, or tissue-engineered technologies to treat or prevent disease, though its exact biological mechanism remains proprietary.
- Other names
- BISC-1-Allegro-ATMPBISC1-Allegro-ATMPBISC 1-Allegro-ATMP
Beyond the preview
Go deeper on BISC-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BISC-1.